MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Research on the modifier gene of Hereditary spinocerebellar ataxia type 2

    JLW. Wang, ZL. Liu (Changsha, China)

    Objective: To investigate the influence of CAG trinucleotides repeat of some (CAG)n-containing gene and some gene polymorphisms in AO of SCA2, and analyse the difference…
  • 2019 International Congress

    Convalescent Chorea in West Nile Virus Encephalitis

    A. Kirby, M. Afshari (Chicago, IL, USA)

    Objective: To discuss an unusual case of chorea in WNV encephalitis. Background: The "neuroinvasive" form of human infection with West Nile virus (WNV) is known…
  • 2019 International Congress

    Isolated unilateral tensor veli palatini myoclonus causing objective tinnitus without palatal elevation

    C. Selvadurai, S. Schaefer (New Haven, CT, USA)

    Objective: To describe a case of unilateral ear clicking caused by isolated tensor veli palatini myoclonus without palatal elevation. Background: Palatal myoclonus may be secondary…
  • 2019 International Congress

    Hydralazine protects nigrostriatal dopaminergic neurons from MPP+ and MPTP induced neurotoxicity: Roles of Nrf2-ARE signaling pathway

    XF. Guo, T. Wang, J. Huang, N. Xiong, C. Han, K. Ma, Y. Xia, F. Wan, JJ. Hu, SJ. Yin, L. Kou, YD. Sun, JW. Wu (Wuhan, China)

    Objective: In this study, we tested whether hydralazine can attenuate 1-Methyl-4-phenylpyridinium (MPP+) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- induced neurotoxicity in vitro and in vivo by activating Nrf2…
  • 2019 International Congress

    Safinamide ameliorates motor deficits and plastic alterations before the onset of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease

    M. Sciaccaluga, P. Mazzocchetti, G. Bastioli, V. Ghiglieri, B. Picconi, A. Tozzi, C. Caccia, C. Keywood, G. Padoani, P. Calabresi (Perugia, Italy)

    Objective: To investigate the effects of safinamide (saf) on synaptic plasticity of spiny projection neurons (SPNs) and the antiparkinsonian effect in dopamine (DA) denervated rats…
  • 2019 International Congress

    Isolated delusion in idiopathic Parkinson’s disease: particularities in a subgroup of patients

    A. Gonçalves, A. Delgado, J. Velosa, R. Simões, J. Vale (Loures, Portugal)

    Objective: Characterize the subgroup of Parkinson’s Disease (PD) patients with isolated delusions. Background: Psychotic features in patients with PD, especially delusions, usually are thought to…
  • 2019 International Congress

    Clinical hypnosis in functional movement disorders: a potential therapeutic strategy

    C. Buiza-Aguado, C. Ordas-Bandera, M. Guillan-Rodriguez, J. Del Val, PJ. Garcia Ruiz-Espiga, JC. Martinez-Castrillo, I. Parees-Moreno, A. Alonso-Canovas (Madrid, Spain)

    Objective: To present a patient with a functional movement disorder who was successfully treated with clinical hypnosis. Background: Functional movement disorders (FMD), specially fixed dystonia,…
  • 2019 International Congress

    The role of stress-related genes and childhood trauma in the clinical phenotype of Functional Movement Disorders

    P. Spagnolo, C. Maurer, G. Norato, C. Hodgkinson, M. Hallett (Bethesda, MD, USA)

    Objective: The aim of this study was to evaluate the relationship between single nucleotide polymorphisms (SNPs) at the level of stress-related genes, childhood trauma, and…
  • 2019 International Congress

    SNCA G51D missense mutation causing juvenile onset Parkinson’s disease

    C. Cooper, J. Goldman, C. Zabetian, I. Mata, J. Leverenz (Chicago, IL, USA)

    Objective: To report the clinical and genetic features in a Parkinson’s patient with the SNCA G51D missense mutation. Background: α-synuclein (SNCA) gene mutations are recognized…
  • 2019 International Congress

    A novel intronic variant in MAPT causes FTLD-parkinsonism: Implications for regulatory mechanism of MAPT pre-mRNA splicing

    P. Gonzalez-Latapi, B. Bustos, D. Larson, L. Kinsley, N. Siddique, T. Siddique, T. Simuni, E. Bigio, S. Lubbe, R. de Silva, D. Krainc, N. Mencacci (Chicago, IL, USA)

    Objective: To report the identification of a novel intronic variant in MAPT in a patient with familial parkinsonism-frontotemporal lobar degeneration (FTLD). Background: MAPT mutations are…
  • « Previous Page
  • 1
  • …
  • 39
  • 40
  • 41
  • 42
  • 43
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley